Antibodies to native myelin oligodendrocyte glycoprotein do not predict progression front clinically isolated syndrome to multiple sclerosis: complete analysis of the BEtaferon (R) in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study